CureVac NV stock (NL0015436031): Delisting amid liquidation process

CureVac N.V. (CVAC) faces delisting on Nasdaq following a stock liquidation announcement, as reported by Robinhood's corporate actions tracker dated January 6, 2026. Details on the process remain pending.

CureVac N.V., a German biotech firm focused on mRNA technology, has been flagged for delisting from Nasdaq under ticker CVAC due to a pending stock liquidation process. The update appeared in Robinhood's corporate actions tracker on January 6, 2026, noting that details are still pending. This development marks a significant shift for the company, which has been navigating challenges in the competitive mRNA therapeutics space.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: CureVac N.V.
• Sector/industry: Biotechnology / mRNA vaccines and therapeutics
• Headquarters/country: Germany
• Core markets: United States, Europe
• Key revenue drivers: mRNA-based vaccines and cancer therapies
• Home exchange/listing venue: Nasdaq (CVAC, pending delisting)
• Trading currency: USD

CureVac NV: core business model

CureVac NV develops mRNA-based medicines for infectious diseases and cancer. The company, founded in 2000 and headquartered in Tübingen, Germany, pioneered RNA optimization technologies to enhance stability and immunogenicity. Its platform targets prophylactic vaccines, cancer immunotherapies, and protein replacement therapies, with a focus on rapid development cycles compared to traditional methods. For US investors, CureVac's Nasdaq listing provided exposure to Europe's mRNA innovation outside of dominant players.

The firm expanded its US footprint through partnerships, including a notable collaboration with CureVac N.V. strengthening operations as mentioned in a December 2025 market report on US mRNA vaccines, according to openPR as of early 2026. This positioned it in a North American market valued at US$18.96 billion in 2023.

Main revenue and product drivers for CureVac NV

CureVac's pipeline includes CVnCoV, its COVID-19 vaccine candidate, alongside oncology programs like individualized neoantigen therapies. Revenue stems primarily from collaborations, grants, and milestone payments, with limited commercial sales to date. The US mRNA therapeutics market, projected to grow from US$46.32 billion in 2024 to US$200.11 billion by 2033 at a 18.4% CAGR, underscores potential demand drivers, per openPR market analysis published in 2026.

Key partnerships have bolstered its position, including efforts to accelerate mRNA development in the US as of December 2025. For retail investors tracking biotech, CureVac represented a high-risk, high-reward play in next-generation vaccines with direct relevance to US healthcare innovation.

Industry trends and competitive position

The mRNA sector has exploded post-COVID, with North America leading at US$18.96 billion in 2023 market size. CureVac competed with leaders like Moderna and BioNTech but faced setbacks in clinical trials and commercialization. Its delisting aligns with broader pressures on smaller biotechs amid funding squeezes and regulatory hurdles.

Conclusion

CureVac NV's pending delisting via stock liquidation, as noted on January 6, 2026, by Robinhood's tracker, signals major uncertainty for shareholders. While its mRNA platform offered promise in a booming US-relevant market, execution challenges have led to this juncture. Investors should monitor official updates for resolution details amid ongoing sector growth.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.